The abstract is read at the publisher; the summary is JClub's.
In the SHaRe registry, 21% of phenotypically mild hypertrophic cardiomyopathy patients developed MACE over a mean 7±6 years, with atrial fibrillation the most common event.
- Why it matters: Mild-appearing HCM may represent an earlier disease stage, but predictors of major adverse cardiovascular events and progression are not well defined for this subgroup.
- What they did: Using SHaRe, phenotypically mild HCM was defined by disease duration <10 years or age ≤30, NYHA class I, no prior MACE, and LV maximal wall thickness <25 mm; Cox regression and mixed remodeling models assessed incident MACE.
- The result: Progression from NYHA I to ≥II symptoms (n=585; 23%) was linked to higher MACE risk (HR 2.79, 95% CI 2.30–3.39), and increasing age, BMI, LA diameter, LV wall thickness, and LVOT gradient predicted MACE.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.